Agilvax is a biotechnology company developing targeted cancer stem cell immunotherapies and vaccines for infectious diseases. The company’s lead product is AX09, a novel cancer stem cell immunotherapy targeting xCT. xCT is overexpressed on the surface of cancer stem cells and contributes to resistance to chemotherapeutic drugs. AX09 has been shown to significantly inhibit lung metastases in a model of triple negative breast cancer. The company is completing AX09 proof of concept in breast cancer and expanding the use to additional cancers.

Agilvax is also developing, AX03, a next-generation Human Papillomavirus (HPV) vaccine that could potentially provide protection against all high and low-risk HPV types. AX03 is progressing towards a phase 1 clinical trial, and is currently advancing through the large-scale manufacturing process, which is aided by a collaboration with the NIH.

Agilvax’s propriety Virus-Like Particles (VLP) platform technology promotes robust and specific immune responses to foreign and self-antigens. The platform allows the immune system to select the ideal VLP candidate through affinity selection screening of the Company’s expansive and unique VLP library. Selected VLPs will subsequently induce an immune response that mimics the properties of the selecting antibody used in the affinity selection process. The platform also provides the ability to rationally engineer and display specific, previously identified epitopes on the surface of VLPs and perform antibody discovery.
In collaboration with key partners, Agilvax is poised to identify and select lead vaccine and cancer therapeutic candidates. The Agilvax platform offers partners attractive licensing opportunities in a resource efficient manner to quickly test concepts and develop programs with a high probability of success.

The company is able to advance candidates through the preclinical proof of concept process at industry leading speed (six months). The products are also produced in a cost-effective manner and do not require a cold-chain.

**Series A**

- **Goal:** $5M
  - Raised $3M
  - Seeking additional $2M
- **Allocation of $2M**
  - Advance AX09 through preclinical proof of concept
  - Develop additional xCT targeting therapeutics
  - Advance AX03 to clinical in collaboration with NIH

---

**Advisory Board**

- **David Peabody, PhD**
  Professor, University of New Mexico
- **Bryce Chackerian, PhD**
  Associate Professor, University of New Mexico
- **Doug Watts, MS, PhD**
  Professor, University of Texas El Paso
- **Frank Borriello, MD, PhD**
  Baxter, Shire, Takeda, Millenium
- **Enrico Braglia**
  OneLife, Helsinn

Agilvax, Inc.
5901 Indian School Rd NE
Albuquerque, NM 87110

info@agilvax.com
www.agilvax.com